VIA Pharmaceuticals Inc represents a strong commitment to innovation, integrity, and patient well-being. As a leading pharmaceutical company, VIA Pharmaceuticals Inc focuses on developing groundbreaking solutions for cardiovascular diseases. With a customer-centric approach, the company strives to improve the lives of individuals suffering from these ailments. VIA Pharmaceuticals Inc is dedicated to conducting extensive research, leveraging advanced technology, and collaborating with top experts in the field to discover novel therapies. By prioritizing the advancement of cardiovascular health, VIA Pharmaceuticals Inc aims to create a positive impact on global healthcare.

VIA Pharmaceuticals Inc is primarily present in the United States.

VIA Pharmaceuticals Inc, a prominent player in the stock market, has achieved significant milestones throughout its journey. The company's accomplishments include successful completion of Phase 2 clinical trials for its lead product, VIA-2291, a novel cardiovascular drug. Additionally, VIA Pharmaceuticals Inc has attained positive results in the treatment of atherosclerosis and inflammatory diseases. With its unwavering commitment to research and development, VIA Pharmaceuticals Inc continues to pave the way for innovative solutions in the healthcare industry. Investors can rely on the company's dedication to achieving excellence and fostering growth in the stock market.

VIA Pharmaceuticals Inc, founded in 1980, is a biotechnology company specializing in the research and development of medications to treat cardiovascular diseases. Headquartered in San Francisco, California, VIA Pharmaceuticals Inc focuses on developing innovative therapies that target inflammation and promote cardiovascular health. By leveraging its expertise in identifying inflammation biomarkers, the company aims to address the urgent need for improved treatments for diseases such as atherosclerosis, acute coronary syndrome, and peripheral arterial disease. With a dedicated team of researchers and scientists, VIA Pharmaceuticals Inc continues to make significant strides in the field of cardiovascular medicine, offering hope for better patient outcomes.

The main competitors of VIA Pharmaceuticals Inc in the market include companies such as Pfizer, Novartis, AstraZeneca, and Johnson & Johnson.

VIA Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of VIA Pharmaceuticals Inc focuses on the development and commercialization of cardiovascular drug candidates. The company aims to address the unmet needs in the treatment of cardiovascular diseases, including atherosclerosis, by leveraging its expertise in cardiovascular biology and inflammation. VIA Pharmaceuticals Inc aims to identify and develop innovative therapies to reduce the risk of major adverse cardiovascular events, such as heart attacks and strokes. Through its research and development efforts, VIA Pharmaceuticals Inc strives to improve patient outcomes and quality of life by targeting the underlying mechanisms that contribute to cardiovascular disease progression.

Količnik cena/dobiček trenutno ni mogoče izračunati za VIA Pharmaceuticals.

KUV za VIA Pharmaceuticals trenutno ni mogoče izračunati.

AlleAktien kakovostni rezultat za VIA Pharmaceuticals je 4/10.

Prihodki trenutno ne morejo biti izračunani za VIA Pharmaceuticals.

Dobička trenutno ni mogoče izračunati za VIA Pharmaceuticals.

VIA Pharmaceuticals Inc is a US-based biopharmaceutical company specializing in the research and development of new innovative drugs for the prevention and treatment of cardiovascular diseases. The company, founded in 2003 and headquartered in San Francisco, California, currently employs about 30 employees. The business model of VIA Pharmaceuticals Inc is based on the development and commercialization of drugs that reduce the risk of cardiovascular diseases or specifically treat them. The company collaborates closely with leading research institutions to develop innovative approaches and new drugs. VIA Pharmaceuticals Inc is divided into various business units, each specializing in different therapy areas. One of the most important areas is the development of drugs that reduce the risk of atherosclerosis, the hardening of blood vessels. The company uses the drug Via-2291, which inhibits the growth of atherosclerotic plaques, to reduce the risk of cardiovascular diseases such as heart attacks and strokes triggered by atherosclerosis. Another important business area is the development of therapeutics for the treatment of acute coronary syndromes (ACS). The company focuses on the discovery and development of drugs that inhibit the inflammatory process in the coronary arteries. VIA Pharmaceuticals Inc uses a combination of several drugs, which are being tested in a series of Phase 2 clinical trials. To drive the development and commercialization of its products, VIA Pharmaceuticals Inc collaborates closely with partners from the pharmaceutical and biotech industry. Particularly important partners in this context are the Biotechnology Industry Organization (BIO), the umbrella organization of the US biotechnology industry, and the American Heart Association (AHA). Collaborations and partnerships are intended to increase the reach of the company's products and technologies. In summary, VIA Pharmaceuticals Inc follows a business model that focuses on the research and development of innovative drugs for the prevention and treatment of cardiovascular diseases. With its technologies, products, and partnerships, the company is well positioned to serve the growing healthcare market and to take a leading role in the industry.

VIA Pharmaceuticals izplača dividendo v višini 0 USD, razdeljeno na izplačil letno.

Dividende za VIA Pharmaceuticals trenutno ni mogoče izračunati ali pa podjetje ne izplačuje dividend.

ISIN od VIA Pharmaceuticals je US92554T1034.

Oznaka delnice VIA Pharmaceuticals je VIAP.

V zadnjih 12 mesecih je VIA Pharmaceuticals izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo VIA Pharmaceuticals predvidoma izplačal dividendo v višini 0 USD.

Trenutni donos od dividend za VIA Pharmaceuticals znaša .

VIA Pharmaceuticals izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

VIA Pharmaceuticals je v zadnjih 0 letih vsako leto izplačeval dividend.

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

VIA Pharmaceuticals je razvrščen v sektor 'Zdravje'.

Da si prejel zadnjo dividendo VIA Pharmaceuticals z dne 7. 7. 2024 v višini 0 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 7. 7. 2024.

Zadnje izplačilo dividende je bilo 7. 7. 2024.

V letu 2023 je VIA Pharmaceuticals 0 USD izplačal kot dividende.

Dividende od VIA Pharmaceuticals se izplačujejo v USD.